CP-100356 hydrochloride NEW
| Price | $69 |
| Package | 1mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-04 |
Product Details
| Product Name: CP-100356 hydrochloride | CAS No.: 142715-48-8 |
| Purity: 99.19% | Supply Ability: 10g |
| Release date: 2025/11/04 |
Product Introduction
Bioactivity
| Name | CP-100356 hydrochloride |
| Description | CP-100356 hydrochloride is an orally active, low micromolar dual inhibitor of MDR1 (P-gp) and BCRP, a nucleotide-derived substrate analogue that inhibits MDR1-mediated Calcein-AM and BCRP-mediated Prazosin transporters. Additionally, CP-100356 inhibits OATP1B1 and induces stomatal opening in the dark. |
| In vitro | In human MDR1-transfected MDCKII cells, CP-100356 hydrochloride inhibited acetoxymethyl calcein (calcein-AM) uptake (IC50 approximately 0.5 +/- 0.07 microM) and digoxin transport (IC50 approximately 1.2 +/- 0.1 microM). Inhibition of prazosin transport (IC50 approximately 1.5 +/- 0.3 microM) in human BCRP-transfected MDCKII cells by CP-100356 hydrochloride confirmed the dual MDR1/BCRP inhibitory properties[1]. |
| In vivo | In vivo inhibitory effects of CP-100356 hydrochloride in rats were examined after coadministration with MDR1 substrate fexofenadine and dual MDR1/BCRP substrate prazosin. Coadministration with increasing doses of CP-100356 hydrochloride resulted in dramatic increases in systemic exposure of fexofenadine (36- and 80-fold increase in C(max) and AUC at a CP-100356 hydrochloride dose of 24 mg/kg). Significant differences in prazosin pharmacokinetics were also discernible in CP-100356 hydrochloride-pretreated rats as reflected from a 2.6-fold increase in AUC.[1]. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (1.67 mM), Sonication is recommended. DMSO : 5 mg/mL (8.37 mM), Sonication is recommended. |
| Keywords | CP-100356 Hydrochloride | BCRP |
| Inhibitors Related | Atazanavir | Trifluoperazine dihydrochloride | Verapamil hydrochloride | Encequidar mesylate | Bicyclol | Polyoxyethylene stearate | Elacridar | P-gp inhibitor 1 | Tariquidar | Cinchonine | Bifendate | Atazanavir sulfate |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00/50mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-21 | |
| $300.00/25kg |
VIP6Y
|
Sichuan Zhuoyu Yantang Technology Co., Ltd.
|
2025-09-09 | |
| $0.00/10mg |
VIP8Y
|
Guangzhou PI PI BIOTECH INC
|
2020-06-19 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY